



Cite this: *RSC Adv.*, 2019, 9, 7277

DOI: 10.1039/c9ra90017a


[www.rsc.org/advances](http://www.rsc.org/advances)

## Correction: Development of hollow ferrogadolinium nanonetworks for dual-modal MRI guided cancer chemotherapy

Ting Tang,<sup>ab</sup> Xiao Sun,<sup>\*c</sup> Xuedong Xu,<sup>d</sup> Yifeng Bian,<sup>a</sup> Xiaojie Ma<sup>a</sup> and Ning Chen<sup>\*a</sup>

Correction for 'Development of hollow ferrogadolinium nanonetworks for dual-modal MRI guided cancer chemotherapy' by Ting Tang *et al.*, *RSC Adv.*, 2019, 9, 2559–2566.

The authors regret that Scheme 1 in the original article included some incorrect data under the cancer chemotherapy part of the scheme. The correct version of Scheme 1 is presented below.



Scheme 1

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

<sup>a</sup>Jiangsu Key Laboratory of Oral Diseases, Nanjing Medical University, Nanjing, 210029, China. E-mail: dentistchenning@126.com

<sup>b</sup>Department of Dental Implantology, Hefei Stomatology Hospital, Clinical School of Anhui Medical University, Hefei, 230001, China

<sup>c</sup>Department of Chemical and Biomolecular Engineering, National University of Singapore, Singapore 117585, Singapore. E-mail: xiaosun8000@163.com

<sup>d</sup>China Shijiazhuang Pharmaceutical Group Co., Ltd., Shijiazhuang, 050038, China

